Searched for
PEGFILGRASTIM
These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsThere are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...- Lupin gets USFDA nod for biosimilar drugLupin gets USFDA approval for Armlupeg, a biosimilar to Neulasta, to treat neutropenia in cancer patients. The drug will be manufactured at...
- Intas Pharma completes acquisition of UDENYCA biosimilar for $558 millionIntas Pharma finalized its acquisition of UDENYCA, a biosimilar to Neulasta, from Coherus Life Sciences for $558 million in December 2024. ...
- Drug maker Lupin inks licensing pact with Axantia for PegfilgrastimPegfilgrastim is indicated to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients receiving chemotherap...
- Lupin announces USFDA acceptance for a biosimilar applicationThe pegfilgrastim filing is the company's first biosimilar filing in the US and is a milestone in the drug maker's research and innovation ...
- Reduce Biocon, target price Rs 250: EdelweissThe stock is trading at 32 times FY22E EPS, which factors in the benefit from potential launches, but not the risks involved.
- Biocon jumps 4% on launch of drug Fulphila in CanadaBiocon has shared or co-exclusive commercialisation rights with Mylan for the product in the rest of the world.
- Biocon, Mylan launch cancer drug in CanadaFulphila, co-developed by Biocon Biologics and Mylan, was the first biosimilar pegfilgrastim to be approved in the US and was launched in J...
- Biocon, Mylan launch cancer drug in AustraliaFulphila, co-developed by Biocon Biologics and Mylan, was the first biosimilar pegfilgrastim to be approved in the US and was launched in J...
- Latest launches to help Biocon reach billion-dollar biosimilar sales by 2022: Kiran Mazumdar ShawHerceptin is a biosimilar trastuzumab is going to be a major launch for both Biocon & Mylan.
- Biocon, Mylan get USFDA nod for pegfilgrastim drug substance licenceThis additional approval of its new manufacturing facility for pegfilgrastim in Bengaluru will enable the biotechnology major to enable its...
- Desi pharma companies top in biosimilars globallyBiosimilars are approved versions of biopharmaceuticals — complex medicines manufactured using live organisms, as against conventional drug...
- Biocon-Mylan's cancer drug gets USFDA nodFulphila is expected to contribute to Biocon’s revenue in FY19, as well as to its profits through a profitshare arrangement with Mylan.
- Biocon shares gain on updates on proposed biosimilars Trastuzumab and PegfilgrastimOn the BSE, 1.61 lakh shares were traded on the counter so far in the trade.
- Biocon rallies over 7% as USFDA issues CRL for proposed biosimilarThis product is a part of the biosimilars portfolio being developed jointly by Biocon and Mylan, the company said in a BSE filing.
- USFDA issues CRL for proposed biosimilar Pegfilgrastim: BioconThe company said it does not expect the CRL to impact the timing of the launch of biosimilar Pegfilgrastim in the US market.
- Biocon gets CRL from USFDA for anti-cancer drugThe company, however, said it does not expect this CRL to impact the commercial launch timing of biosimilar Pegfilgrastim in the US.
- USFDA accepts Mylan's BLA for proposed biosimilar PegfilgrastimThe proposed biosimilar Pegfilgrastim is one of the six biologic products co-developed by Mylan and Biocon for the global marketplace, the ...
- US FDA accepts Biocon-Mylan biosimilar application for proposed anti-cancer bio-similarBiocon said that the FDA's acceptance for review of this biosimilar is an outcome of the company’s strong R&D and manufacturing capabilitie...
- EMA accepts marketing application of Biocon, Mylan productMylan and Biocon, who co-developed the proposed biosimilar, received EMA's acceptance of the submission for review, Biocon said in a statem...
Load More
